Stobadine-modulated human neutrophil functional responsiveness: effect on particular and soluble stimulation

The effect of stobadine on degranulation (myeloperoxidase release) and on oxidative burst, measured as superoxide anion production, was investigated in human neutrophils activated with receptor-specific (fMLP, opsonized zymosan) and nonreceptor stimuli (PMA, A 23187). Wortmannin, a specific inhibitor of 1-phosphatidylinositol 3-kinase, significantly inhibited fMLP-stimulated generation only. This effect was pronounced by stobadine. Stobadine dose-dependently decreased superoxide generation and myeloperoxidase release after receptor-specific stimuli, with the highest effect on fMLP stimulation of superoxide generation and on opsonized zymosan stimulation of myeloperoxidase release.

Effect of stobadine on opsonized zymosan stimulated generation of reactive oxygen species in human blood cells

To predict more precisely the effect of stobadine, a pyridoindole antioxidant agent, in the whole organism, we studied its effect on opsonized zymosan-stimulated free radical generation in whole blood, on superoxide generation in the mixture of PMNL : platelets (1:50), as well as on superoxide generation and myeloperoxidase release in isolated PMNL. Without stimulation, stobadine had no effect on reactive oxygen species (ROS) generation and myeloperoxidase release. Stobadine in a concentration of 10 or 100 micromol/l significantly decreased luminol-enhanced chemiluminescence in opsonized zymosan-stimulated whole blood. In concentrations of 10 and 100 micromol/l, it reduced myeloperoxidase release from isolated neutrophils. Stobadine significantly decreased superoxide generation in isolated neutrophils in 100 micromol/l concentration. Its effect was much less pronounced in the mixture of neutrophils and platelets in the ratio close to physiological conditions (1:50). Our results suggest that stobadine might exert a beneficial effect in diseases or states where superfluous ROS generation could be deleterious.

Effect of stobadine on oxygen free radical generation in stimulated human polymorphonuclear leukocytes

The generation both superoxide and a mixture of reactive oxygen species was recorded in a suspension of human polymorphonuclear leukocytes stimulated with phorbol myristate acetate. While stobadine dose-dependently decreased chemiluminescence, only its highest concentration used reduced significantly superoxide generation. The results suggest that stobadine is a more effective scavenger of free radicals rather than a quencher of superoxide anion.

Effects of histamine H1 antagonist dithiaden on acetic acid-induced colitis in rats

To assess the possible involvement of mast cells and/or their mediators in inflammatory bowel diseases, the effect of the histamine H1 antagonist Dithiaden was studied on a model of acetic acid-induced colitis in rats. Dithiaden pretreatment by intracolonic administration was found to reduce the extent of acute inflammatory colonic injury. This was manifested by a decrease in the score of gross mucosal injury, by lowered colonic wet weight and by diminished myeloperoxidase activity reflecting reduced leukocyte infiltration. Vascular permeability and gamma-glutamyl transpeptidase activity, elevated by acetic acid exposure, were decreased after Dithiaden pretreatment. The results indicate that locally administered Dithiaden may protect the colonic mucosa against an acute inflammatory attack by interfering with the action of the major mast cell mediator histamine.

Effect of stobadine on human stimulated polymorphonuclear leukocytes

The effect of stobadine (0.1-100 microM) on human polymorphonuclear (PMN) leukocytes stimulated with N-formyl-methionyl-leucyl-phenylalanine, a specific receptor activator, or with the calcium ionophore, A-23187 (receptor bypassing stimulus) was investigated with respect to: i) superoxide generation, ii) beta-glucuronidase release and iii) 3[H]-arachidonic acid liberation. Stobadine was found to exert an inhibitory effect on N-formyl-methionyl-leucyl-phenylalanine but not on A-23187-stimulated PMN leukocytes. The effect was more intensive on superoxide generation and beta-glucuronidase release than on 3[H]-arachidonic acid liberation. These results indicate that the inhibitory effect of stobadine is most probably via a mechanism dependent on signal transduction across the plasma membrane. This effect may occur through inhibition of arachidonate signal transduction through a regulatory G-protein.

Human polymorphonuclear leukocytes: effect of chloroquine on aggregation, arachidonic acid liberation and thromboxane B2 generation

The effects of the antimalarial drug chloroquine (CQ) on arachidonic acid (AA) liberation from, thromboxane B2 (TXB2) formation in, and aggregation of isolated human polymorphonuclear (PMN) leukocytes stimulated with N-formyl-methionyl-leucyl-phenyl-alanine (FMLP) were investigated. CQ decreased aggregation of stimulated PMN leukocytes, however in contrast to AA liberation and TXB2 formation, lower concentrations were more effective than the highest one used. This effect may be associated with an increase in intracellular pH, reported to be induced by higher CQ concentrations, possibly counteracting the inhibition of aggregation, and/or eliminating negative feed back control of aggregation by lack of prostaglandins.

Effect of chloroquine on mast cell membranes

The effect of chloroquine (CQ) on phospholipid turnover and de novo synthesis in isolated rat mast cells (IRMC) was studied by determining the incorporation of 32P and 14C-glycerol into IRMC phospholipids. Incubation of mast cells with chloroquine increased 32P incorporation into PI and PS whilst it decreased 32P incorporation into PC, PE and PA. In mast cells pretreated with CQ and subsequently stimulated with compound 48/80, 32P incorporation into PI, PS and PA fractions was enhanced, while it was decreased into PC and PE, in comparison to 48/80 stimulated IRMC. 14C-glycerol incorporation into total IRMC phospholipids was not significantly changed by CQ and compound 48/80 treatment and neither was any dose-dependent effect of CQ on individual phospholipids detected. Our results indicate that chloroquine, similarly to other cationic amphiphilic drugs, may alter membrane PL turnover without changing de novo synthesis of phospholipids.

Effect of chloroquine on isolated mast cells

Chloroquine liberated a relatively low amount of histamine from isolated rat mast cells. In a dose-dependent way, this drug inhibited histamine liberation from mast cells stimulated with compound 48/80, A23187, concanavalin A plus phosphatidylserine (Con A + PS) and abolished histamine liberation induced by exaprolol. The degranulation was decreased in cells stimulated with 48/80, Con A + PS and exaprolol. Chloroquine significantly inhibited the formation of thromboxane B2 in mast cells stimulated with 48/80, Con A + PS and A23187. We assume that chloroquine interferes with mast cells at a plasmic membrane site as well as intracellularly.

Atenolol, exaprolol and mast cell membranes

Lipophilic exaprolol and hydrophilic atenolol differ in their interaction with mast cell membranes. Exaprolol, as compared with atenolol, significantly decreased 32P incorporation into, but increased arachidonic acid liberation from, membrane phospholipids. Moreover, exaprolol significantly decreased phosphate incorporation in compound 48/80 and ConA-PS treated cells and decreased thromboxane formation in stimulated cells. On the other hand, atenolol decreased significantly only arachidonate liberation from stimulated mast cells. These results corroborate to some extent the effect of exaprolol and atenolol on histamine liberation which correlates with their membrane perturbing properties.

[The effect of adrenergic beta receptor blockers on phospholipid metabolism in mast cells]

The aim of this study was to determine whether beta adrenergic receptor blocking drugs exaprolol, metipranolol and propranolol effect the metabolism of phospholipids in isolated rat mast cells. The phospholipids were labelled by 3H-arachidonic acid (3H-AA) and 32P. Exaprolol, metipranolol and propranolol significantly modulated 32P incorporation into phospholipids of resting and 48/80 stimulated cells. Atenolol had no effect. Studies with 3H-AA Labelled mast cells showed an enhanced liberation of arachidonate related radioactivity on exaprolol and propranolol treatment. The results indicated that 3H-activity was lost mainly from phosphatidylethanolamine. Atenolol and metipranolol significantly decreased the 48/80 stimulated 3H-AA release.

[Analysis of the adverse effects of drugs at the cellular and subcellular levels]

A release of histamine after the lipophilic betablockers exaprolol and propranolol correlates with their capability of displacing the bound membrane Ca2+ and increasing the disorder of phospholipidic membranes of the isolated mast cells. Electron microscopy confirmed intracellular displacement of histamine from granules of mast cells after exaprolol without marked structural changes on the plasmatic membrane. Hydrophilic and selective atenolol, which does not possess a histamine-liberating effect, decreases spontaneous transfer of the intracellular calcium, decreases the disorder of the mast-cell membranes, and together with exaprolol and propranolol inhibits, in dose-dependence way, the gain of extracellular histamine in cells. The inhibitory effect of EDTA, tetrodotoxine and suramine on histamine release after exaprolol explains the non-receptor mechanism of exaprolol effect, which confirms a possibility of induction of adverse effects of blockers of the beta-adrenergic receptor in the development of a bronchospasm.

The effect of beta-adrenoceptor blocking drugs on histamine liberation, prostaglandin synthesis and phospholipid turnover in isolated mast cells stimulated with concanavalin A

Exaprolol, metipranolol and propranolol decreased significantly histamine liberation, degranulation, 45Ca uptake and thromboxane B2 formation in isolated rat mast cells stimulated with concanavalin A and phosphatidylserine. Moreover, exaprolol and metipranolol decreased 32P incorporation into membrane phospholipids and metipranolol and propranolol reduced the liberation of arachidonic acid from membrane phospholipids of stimulated mast cells. Exaprolol significantly increased the arachidonic acid liberation from these cells. Possible mechanisms of interaction of beta-adrenoceptor blocking drugs with isolated mast cells are discussed.

Histamine liberation as a result of nonreceptor interaction

The highly lipophilic drug exaprolol liberates histamine from isolated mast cells and decreases the uptake of extracellular histamine in a dose-dependent manner. Intracellular histamine depletion was confirmed by electron microscopy and was accompanied by calcium displacement from intracellular storage sites. The significant decrease in membrane fluidity due to exaprolol was temperature-dependent and was most probably a result of its high membrane affinity and intracellular penetration. Membrane perturbation by exaprolol may account for this nonreceptor interaction. This could contribute to the understanding of adverse reactions to beta-adrenoceptor blocking drugs.

Membrane perturbing activity of beta-adrenoceptor blocking drugs in isolated rat mast cells

Beta-adrenoceptor blocking (BAB) drugs perturb the membranes of isolated rat mast cells. Membrane fluidisation was temperature dependent and was determined by the liposolubility of the BAB drugs. The secretory index, evaluated as the ratio between histamine liberation and degranulation, correlated with the membrane order parameter of the mast cell membranes. The rank order of potency for mast cell activation and membrane fluidisation was: exaprolol greater than propranolol greater than metipranolol greater than atenolol.

Effect of beta-adrenoceptor blocking drugs on 32P incorporation into and arachidonic acid liberation from phospholipids in stimulated rat mast cells

The lipophilic beta-adrenoceptor blocking (BAB) drugs metipranolol, propranolol and exaprolol significantly decreased 48/80- and A23187-induced 32P incorporation into rat mast cell phospholipids. Exaprolol was the most active, followed by propranolol and metipranolol. Atenolol and metipranolol significantly decreased the 48/80-stimulated, and metipranolol and exaprolol the A23187-stimulated 3H-arachidonic acid liberation from isolated mast cells.

Beta-adrenoceptor blocking drugs and calcium transport in isolated rat mast cells

The beta-adrenoceptor blocking (BAB) drugs exaprolol (EXA), metipranolol (MET) and propranolol (PRO) inhibited histamine liberation and degranulation from isolated rat mast cells stimulated with the calcium ionophore A23187. MET was the most and EXA the least active. Atenolol (ATE) had no effect. Inhibition by BAB drugs of secretion induced with A23187 was not accompanied by any change in 45Ca uptake. On the other hand, EXA, MET and PRO significantly decreased 45Ca uptake by mast cells stimulated with 48/80. The effect of BAB drugs on inhibition of A23187-induced secretion from isolated mast cells was dependent on the lipid solubility of the studied drugs.

Effect of stobadine on stimulated isolated mast cells

Stobadine, an antiarrhythmic drug with antihistaminic properties, did not liberate histamine from mast cells in vitro. Compound 48/80-stimulated histamine liberation and degranulation was decreased in the presence of stobadine in a dose-dependent way. The spontaneous as well as stimulated calcium displacement in mast cells was significantly decreased by stobadine. Stobadine most probably possesses a membrane-stabilizing effect on isolated rat mast cells.

On the relationship between incorporation of 32P into phospholipids and binding of beta-adrenoceptor blocking drugs to isolated mast cells

The lipophilic beta-adrenoceptor blocking drugs exaprolol and propranolol significantly decreased the incorporation of 32P into phosphatidylethanolamine, phosphatidylcholine and phosphatidylinositol of isolated rat mast cells. In contrast, the hydrophilic drugs metipranolol, practolol and atenolol increased the incorporation of 32P into phosphatidylethanolamine, phosphatidylserine and phosphatidylinositol. The inhibition of 32P incorporation by lipophilic drugs correlated with the high binding of these drugs to mast cells.

Histamine liberation and membrane fluidisation of mast cells exposed to the beta-adrenoceptor blocking drug propranolol

Propranolol liberates histamine from isolated mast cells and decreases the uptake of extracellular histamine in a dose-dependent way. Histamine liberation due to propranolol is accompanied by calcium displacement from intracellular storage sites. The significant increase in membrane fluidity due to propranolol is temperature dependent. The perturbation of membranes is most probably the explanation of propranolol's interaction with isolated rat mast cells which results in altered histamine transportation.

Amine transport in isolated rat mast cells treated with betaadrenoceptor blocking drugs

Histamine and serotonin uptake in isolated rat mast cells is decreased in the presence of betaadrenoceptor blocking (BAB) drugs. Such inhibition is dose-dependent and is evidently higher for the inhibition of serotonin uptake. The most potent drugs were the highly lipophilic compounds Kö 1124 and propranolol. No difference was found among the various BAB drugs in their ability to decrease histamine uptake. It is evident from the ratio between histamine and serotonin liberation on one side, to the uptake of both amines in mast cells on the other side, that with the exception of Kö 1124, all investigated BAB drugs possesses higher inhibition of extracellular amine uptake in comparison with histamine and serotonin liberation. Such an effect might be a result of a primary interaction of BAB drugs with mast cells at the plasma membrane.

On the interaction of beta-adrenoceptor-blocking drugs with isolated mast cells

The interaction of beta-adrenoceptor blocking drugs (BAB drugs) with isolated mast cells resulted, according to the compound, in either a liberation of biogenic amines or an inhibition of stimulated amine release. The liberatory drugs exaprolol and Kö 1124 decreased the level of cAMP, stimulated the activity of cyclic nucleotide-phosphodiesterase, decreased the incorporation of orthophosphate into membrane phospholipids and rapidly displaced calcium from binding sites in mast cells. The inhibitory drugs alprenolol, metipranolol, oxprenolol, practolol and propranolol, possessing lower liposolubility, produced opposite effects. Drugs from both groups displaced histamine from binding sites in isolated mast cell granules. The interaction of BAB drugs with mast cells is a result of non-specific rather than specific receptor interactions. Inhibitory drugs interfere with mast cells at membrane sites while liberatory drugs penetrate the membrane, thus acting both at the level of membrane and intracellularly.

Quantitative correlation between histamine and 35S release from isolated rat mast cells due to the beta-adrenergic blocking drug Kö 1124

An attempt was made to explain the mechanism of histamine release from isolated rat mast cells induced by the beta-adrenergic blocking drug Kö 1124. This drug at the highest concentration used released 12 times more histamine than most other investigated beta-blockers. The release of histamine with Kö 1124 was dose and temperature dependent. The maximal histamine release was at pH 8 and in the absence of calcium ions. Increased calcium concentration decreased histamine release significantly. The effect of Kö 1124 on histamine release from mast cells was inhibited only by cocaine and 2,4-dinitrophenol; other metabolic inhibitors were ineffective. The histamine release due to Kö 1124 was not followed by an equal release of 35S. Isoprenaline in equimolar concentration decreased histamine release induced by Kö 1124 significantly. The release of 35S-labelled granules was decreased or blocked by isoprenaline.